Seattle Genova offers outstanding quality AAV packaging services to benefit your AAV-based gene therapy experiments. We have improved a series of proprietary technologies and reagents that have largely improved recombinant AAV production protocols in terms of titer, purity, potency and consistency, particularly for the AAV vector systems utilized in our vector cloning services. As a consequence, we have a growing base of highly satisfied customers who come back to us time after time for their AAV vector cloning and AAV packaging requirements.
Kidney is the vital parts of the humoral regulation and strengthens the nutrients and metabolites of the body balanced. kidney dysfunction may arise in chronic kidney disorder, which has been commonly acknowledged as a severe problem influencing public health. Therapies such as dialysis or kidney transplantation are commonly costly and may cause numerous severe side effects. Therefore, developing new therapeutic strategies for treating patients with kidney disease is essential and crucial.
Renal fibrosis, a hallmark of chronic kidney disease (CKD), is defined by the accumulation of additional extracellular matrix proteins secreted by myofibroblasts. Unfortunately, there are no anti-fibrotic drugs approved for solution of CKD.
Gene therapy includes delivery of exogenous DNA to give a therapeutic protein. Ideally, a gene therapy vector should be non-toxic, non-immunogenic, easy to generate, and creative in protecting and delivering DNA into target cells.
The adeno-associated virus (AAV) vector has become a powerful tool in providing genes to mammalian cells because of its capacity to infect both dividing and non-dividing cells, its low immune response and a favorable safety profile in humans. The ability to provide genetic material specifically to myofibroblast progenitors could enable new therapeutic approaches to treat kidney fibrosis.
Cell-type Specific Targeting Strategy
Strategies that target different kidney cells can provide researchers a vast selection when developing diagnostic or therapeutic strategies for renal diseases that influence particular kidney cell types.
Seattle Geova provide Kidney-targeted delivery services regarding diseases, subcellular organelles, and infectious microorganisms
How We Work?
Suitable serotypes for Kidney
We begin by subcloning the gene of interest (GOI), shRNA or gRNA into an associated pAAV cis-plasmid.
Large-scale Production (Optional)
Large-scale preparation of the pAAV cis-plasmid and complimentary plasmids utilizing Qiagen Endo-free Mega Prep kits.
Large scale Transfection
Large-scale transfection of engaged plasmids into 40x15cm plates of HEK293 cells.
Harvest the AAV production cells and purify the AAVs through a sequence of CsCl centrifugations.
Find the titer of the viral stock (in genome copy number per ml, or GC/ml) through quantitative real-time PCR.
Genome-wide AAV Products
• Over-Expression Products
• shRNA Products
Key Features and Benefits
•Ready to utilize for in vitro and in vivo applications
•High titer: improved transduction efficiency
•Transduction of dividing and non-dividing cells
•Expert Technical Support
•Quality and user friendly
2.Wang, J.; et al. Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease. Biomaterials science. 2017, 5(8): 1450-1459.
3.Zhou, P.; et al. Kidney-targeted drug delivery systems. Acta Pharmaceutica Sinica B. 2014, 4(1):37-42.
Thank you for your interest in our Kidney Targeting AAV Production Services services. Please complete the form below and we will contact you shortly.
Fields indicated by an * are required.